Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Other financing activities (2016 - 2025)

Historic Other financing activities for Anika Therapeutics (ANIK) over the last 13 years, with Q3 2025 value amounting to $13000.0.

  • Anika Therapeutics' Other financing activities fell 3809.52% to $13000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 million, marking a year-over-year decrease of 3483.1%. This contributed to the annual value of $2.6 million for FY2024, which is 2077.14% up from last year.
  • Per Anika Therapeutics' latest filing, its Other financing activities stood at $13000.0 for Q3 2025, which was down 3809.52% from $83000.0 recorded in Q2 2025.
  • Anika Therapeutics' 5-year Other financing activities high stood at $2.3 million for Q1 2024, and its period low was -$218000.0 during Q4 2021.
  • Moreover, its 5-year median value for Other financing activities was $107000.0 (2023), whereas its average is $440842.1.
  • Over the last 5 years, Anika Therapeutics' Other financing activities had its largest YoY gain of 162800.0% in 2023, and its largest YoY loss of 70000.0% in 2023.
  • Over the past 5 years, Anika Therapeutics' Other financing activities (Quarter) stood at -$218000.0 in 2021, then soared by 99.54% to -$1000.0 in 2022, then crashed by 700.0% to -$8000.0 in 2023, then surged by 1050.0% to $76000.0 in 2024, then tumbled by 82.89% to $13000.0 in 2025.
  • Its last three reported values are $13000.0 in Q3 2025, $83000.0 for Q2 2025, and $1.5 million during Q1 2025.